BRAF and skin neoplasm: The CPM #10 covering almost the entire skin cancer cell lines included the pharmaceutical agent PLX4720 (vemurafenib) and BRAF mutation; the efficacy of vemurafenib has been tested in several clinical trials for treating unresectable or metastatic melanoma with BRAF V600E mutation (Chapman et al., 2011).